168 related articles for article (PubMed ID: 35182375)
1. Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms.
Meregaglia M; Tarricone R
Pharmacoecon Open; 2022 Jul; 6(4):595-603. PubMed ID: 35182375
[TBL] [Abstract][Full Text] [Related]
2. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
[TBL] [Abstract][Full Text] [Related]
3. 'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases.
Meregaglia M; Whittal A; Nicod E; Drummond M
Pharmacoeconomics; 2020 Jun; 38(6):557-574. PubMed ID: 32152892
[TBL] [Abstract][Full Text] [Related]
4. A systematic literature review of health state utility values in head and neck cancer.
Meregaglia M; Cairns J
Health Qual Life Outcomes; 2017 Sep; 15(1):174. PubMed ID: 28865475
[TBL] [Abstract][Full Text] [Related]
5. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients.
Paracha N; Abdulla A; MacGilchrist KS
Health Qual Life Outcomes; 2018 Sep; 16(1):179. PubMed ID: 30208899
[TBL] [Abstract][Full Text] [Related]
7. Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants.
van Santen S; Out JJ; Zoutman WH; Quint KD; Willemze R; Vermeer MH; Tensen CP
Biochem Biophys Rep; 2021 Jul; 26():101007. PubMed ID: 34027133
[TBL] [Abstract][Full Text] [Related]
8. Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS.
Svedbom A; Borgström F; Hernlund E; Ström O; Alekna V; Bianchi ML; Clark P; Curiel MD; Dimai HP; Jürisson M; Uusküla A; Lember M; Kallikorm R; Lesnyak O; McCloskey E; Ershova O; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jönsson B; Kanis JA
Qual Life Res; 2018 Mar; 27(3):707-716. PubMed ID: 29235059
[TBL] [Abstract][Full Text] [Related]
9. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator.
Ottevanger R; van Beugen S; Evers AWM; Willemze R; Vermeer MH; Quint KD
JAAD Int; 2022 Dec; 9():57-64. PubMed ID: 36147217
[TBL] [Abstract][Full Text] [Related]
10. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review.
Brockbank J; Krause T; Moss E; Pedersen AM; Mørup MF; Ahdesmäki O; Vaughan J; Brodtkorb TH
Health Qual Life Outcomes; 2021 Mar; 19(1):94. PubMed ID: 33736649
[TBL] [Abstract][Full Text] [Related]
11. Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatology-specific instruments.
Herbosa CM; Semenov YR; Rosenberg AR; Mehta-Shah N; Musiek AC
J Eur Acad Dermatol Venereol; 2020 May; 34(5):995-1003. PubMed ID: 31630443
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and severity of pruritus in cutaneous T cell lymphoma.
Vij A; Duvic M
Int J Dermatol; 2012 Aug; 51(8):930-4. PubMed ID: 22788808
[TBL] [Abstract][Full Text] [Related]
14. Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL).
Williams K; Gibson A; McNamara L; Jones T; Lloyd AJ
J Med Econ; 2020 Oct; 23(10):1142-1150. PubMed ID: 32644862
[TBL] [Abstract][Full Text] [Related]
15. EQ-5D-Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review.
Golicki D; Jaśkowiak K; Wójcik A; Młyńczak K; Dobrowolska I; Gawrońska A; Basak G; Snarski E; Hołownia-Voloskova M; Jakubczyk M; Niewada M
Value Health; 2020 Jul; 23(7):953-968. PubMed ID: 32762998
[TBL] [Abstract][Full Text] [Related]
16. Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description.
D'Agostino P; Kent A; Sharp E; Schmidt F; Turini M
Drugs Context; 2020; 9():. PubMed ID: 32821261
[TBL] [Abstract][Full Text] [Related]
17. Health State Utility Values of Type 2 Diabetes Mellitus and Related Complications: A Systematic Review and Meta-Analysis.
Redenz G; Ibaceta MC; Aceituno D; Balmaceda C; Espinoza MA
Value Health Reg Issues; 2023 Mar; 34():14-22. PubMed ID: 36371899
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis.
Tsang Y; Gu T; Sharma G; Raspa S; Drake B; Tan H
J Dermatolog Treat; 2018 Dec; 29(8):747-753. PubMed ID: 29733229
[TBL] [Abstract][Full Text] [Related]
19. Pruritus in cutaneous T-cell lymphoma: a review.
Ahern K; Gilmore ES; Poligone B
J Am Acad Dermatol; 2012 Oct; 67(4):760-8. PubMed ID: 22285672
[TBL] [Abstract][Full Text] [Related]
20. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
